Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco DB Commodity Index Tracking Fund — how do they compare? Adaptive Biotechnologies Corp trades at $19.95 (market cap $3.33B), while Invesco DB Commodity Index Tracking Fund trades at $27.85. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | DBC | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $22.37 | $31.69 |
52-Week Low | $10.24 | $21.62 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DBC trades at $27.00, up 1.62% with a bullish technical signal supported by strong momentum indicators. The commodity ETF shows resilience amid inflation concerns, recently hitting 52-week highs according to Zacks Investment Research (April 29, 2026). Current price action consolidates near key support/resistance levels with mixed moving average signals suggesting near-term consolidation potential.
Outlook remains positive as commodities gain traction for inflation hedging, though the ETF faces headwinds from commodity price volatility and geopolitical risks. The equal-weight portfolio strategy showing strong 2026 performance provides additional tailwinds for diversified commodity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
